FDA approves first combination pill to treat hepatitis C

FDA approves first combination pill to treat hepatitis C

World Cancer Day 4th February

World Cancer Day – February 4, is a key date every year for all of the international cancer communities. Globally, more people die from cancer than from AIDS, malaria, and tuberculosis combined. Each year, 14.1 million people learn they have cancer, and 8.2 million people die from the disease worldwide. The World Health Organization (WHO) [...]

2015 Biopharma-MEA annual Kickoff Meeting

              The 2015 Biopharma-MEA Annual Takeoff Meeting took place this year in Singapore. The slogan of “BPROUD” standing for “Biopharma People Outreaching Ultimate Dreams”, has been selected for this year meeting reflecting the high level of energy, enthusiasm, and ambitious of the Biopharma-MEA team. This year’s meeting is taking [...]

Biopharma MEA, Win the “2014, Distributor of The Year Award” from Gilead Sciences

Athens, Oct,15, 2014 Biopharma Middle East& Africa proudly received today the “2014, Distributor of The Year Award” from Gilead Sciences. This award is coming in recognition for the efforts and achievements that Biopharma MEA made. The company has been very successful in achieving its planned milestones, building access to many institutions to new innovative therapies, [...]

FDA approves first combination pill to treat hepatitis C

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs [...]

BIOPharma-MEA Leadership Academy

                      Learning development never looked so good! “Inspiring Autonomous Manager” programme takes a break!   The training is a start of another journey to sharpen the managerial skills for Biopharma-MEA management team.